UNITY Biotechnology Announces Appointment of Alexander Nguyen as General Counsel
March 08 2021 - 8:00AM
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology
company developing therapeutics to slow, halt or reverse diseases
of aging, today announced that Alexander Nguyen has been appointed
general counsel.
“Alex brings extensive operational and
regulatory experience in the life sciences industry that will help
him build our company’s legal function,” said Anirvan Ghosh, Ph.D.,
chief executive officer of UNITY. “He is a dynamic leader with deep
roots in the fields of business, government and law. I am pleased
to welcome him to our team and believe his expertise will serve us
well as we continue to advance our clinical pipeline in
ophthalmology and other age-related diseases.”
Mr. Nguyen previously worked for three Roivant
Sciences companies where he served as general counsel at Alyvant,
head of legal at Axovant, and as head of compliance at Roivant
Sciences. His responsibilities included all corporate legal work,
SEC filings, equity financings, venture debt deals, licensing
agreements, corporate governance at board meetings, litigation,
internal investigations, asset recovery, HR, IT, compliance, and
risk management. He also led the drafting and negotiation of term
sheets and oversaw due diligence for acquisition of
commercial-stage assets. Before that, he handled a wide range of
high-stakes litigation and investigations in the private as well as
the public sector, including as deputy section chief and federal
prosecutor at the U.S. Attorney’s Offices in Alexandria and
Philadelphia, respectively, successfully leading dozens of cases
involving cybercrime, data breaches, IP and trade secrets
violations, FDA regulatory offenses, illegal importation of
adulterated and misbranded pharmaceuticals, prescription drug
diversion, white collar crime, identity theft and tax
violations.
Mr. Nguyen also served as assistant White House
counsel, managing and implementing key White House policy
initiatives across Cabinet and federal agencies. He obtained his
undergraduate degree from Harvard University and his law degree
from Yale Law School.
About UNITYUNITY is developing
a new class of therapeutics to slow, halt or reverse diseases of
aging. UNITY’s current focus is on creating medicines to
selectively eliminate or modulate senescent cells and thereby
provide transformative benefit
in age-related ophthalmologic and neurologic diseases.
More information is available
at www.unitybiotechnology.com or follow us
on Twitter and LinkedIn.
Investors
Gilmartin Group
Matt Lane
ir@unitybiotechnology.com
Media
Canale Communications
Jason Spark
Jason.spark@canalecomm.com
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Mar 2024 to Apr 2024
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Apr 2023 to Apr 2024